Curetis N.V.’s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics with syndromic testing designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.

Curetis USA Inc., a wholly owned subsidiary, is the commercialization and distribution center in the United States. In 2018, Curetis received FDA approval for America’s first Lower Respiratory multiplex PCR diagnostic panel – the Unyvero LRT Panel for tracheal aspirate samples. Two years later, the Unyvero LRT BAL for for bronchoalveolar lavage samples got FDA approval. With the Unyvero LRT and LRT BAL, hospitals can diagnose serious Pneumonia infections and target effective antibiotic treatment with the help of syndromic testing faster. Faster, targeted treatment leads to reduced mortality, reduced healthcare costs and better utility of available antibiotics.

Our wholly owned subsidiary Ares Genetics GmbH offers next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines the world’s most comprehensive database on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence.

Mission & Vision

The molecular diagnostic company Curetis aims to deliver innovative diagnostic solutions to help clinicians swiftly combat severe infectious diseases.
Through Curetis technology, we envision a world that is no longer threatened by antibiotic resistant superbugs.

Visionary & Interdisciplinary Management Team

Oliver Schacht, Ph.D.


Mr. Oliver Schacht, a corporate finance professional and expert in the molecular diagnostics industry, has been CEO of Curetis since April 2011 and prior to that was a Supervisory Board Member of Curetis AG from mid-2010 to end of the first quarter in 2011. He was a co-founder and CFO of Epigenomics AG (Berlin, Germany) and the CEO of Epigenomics Inc. (Seattle, USA). Mr. Schacht has extensive experience in developing and implementing commercial strategies and financing measures (including two IPOs), as well as corporate finance, investor relations, PR, marketing and business development. Mr. Schacht also serves on the Board of BIO Deutschland e.V. as its president and previously as treasurer.

Mr. Schacht obtained his Diploma in European Business Administration at the European School of Business in Reutlingen and London in 1994 as well as a Master’s degree and a Ph.D. at the University of Cambridge (UK). During his time at Mercer Management Consulting (now Oliver Wyman) from 1995 to 1999, he worked on projects in M&A, growth strategies and re-organization in the pharmaceutical, biotechnology and other industries.

He has co-founded several start-up companies in biotech, IT and education in Europe and the USA.

Johannes Bacher


Johannes Bacher combines over 20 years of R&D and managerial experience with extensive expertise in research & development, clinical trials, international project management, finance, human resources and legal affairs. Hence, the Curetis co-founder is ideally suited to managing the general R&D and Clinical Trial operations of Curetis.

Johannes has a degree in electrical engineering and has already worked for several international medical technology companies, including Hewlett Packard, Agilent and Philips Medical Systems.

Dr. Achim Plum


Dr. Achim Plum joined the Curetis Management Board in 2015. As Chief Business Officer, Dr. Plum drives corporate and business development of the Curetis Group. Further, his responsibilities include corporate communications, legal, and human resources. Since its incorporation in 2017, Dr. Plum is also one of the managing directors of Ares Genetics GmbH in Vienna, Austria, a new company of the Curetis Group.

Before joining Curetis in 2015, Dr. Plum had the global responsibility for the Area Diagnostics and Biosciences Research in the Technology Center of Siemens Healthcare, now Siemens Healthineers. Before Siemens, Dr. Plum worked for eight years at the publicly listed German-American molecular diagnostics company Epigenomics AG, lastly as Senior Vice President Business & Strategy.

After undergraduate and postgraduate studies in genetics, cell biology, and biochemistry at the University of Bonn (Germany) and the University of East Anglia (Norwich, UK), Dr. Plum received his PhD from the University of Bonn in 1999 for research into novel genetic models of human diseases.

Andreas Boos


With over 25 years of professional experience at Hewlett Packard, Agilent and Philips, Curetis co-founder Andreas Boos boasts a wealth of international experience in developing and implementing solutions for patient monitoring and on-site molecular diagnostics.

As a graduate electrical engineer, Andreas Boos has successfully applied his project management skills to lead the development of several innovative and commercially successful medical devices for the global markets.

In addition to his extensive knowledge of customer requirements, Andreas brings to Curetis a comprehensive understanding of quality systems, standards and global regulatory approval procedures

Chris Emery

President & CEO, Curetis USA

Chris Emery, President & CEO, Curetis USA, Inc.

Chris Emery has joined Curetis as President and CEO of Curetis USA, Inc., bringing more than 20 years of healthcare experience and 10 years in executive leadership roles in the laboratory diagnostics, medical device and pharmaceuticals industries. Chris’ primary focus has been leading the commercial launch and execution for numerous next-generation molecular diagnostic assays in the precision medicine market. Most recently, he was the Chief Commercial Officer – North America for Menarini Silicon Biosystems, where he directed the U.S. sales and business development activities for the DEPArray NxT molecular device as well as the integration of the FDA-cleared CellSearch Circulating Tumor Cell assay. Prior, Chris was the General Manager for Abbott’s PersonalizeDx cancer diagnostics laboratory division, and he also held senior level management roles as Chief Operating Officer at CombiMatrix, VP Sales & Marketing at Response Genetics, and National Sales & Marketing Manager at US LABS, prior to its acquisition by LabCorp. Chris began his career in healthcare with Johnson & Johnson, promoting the antibiotic Levaquin into hospital systems for a wide variety of bacterial infections, including hospital-acquired pneumonia. He obtained his MBA from Pepperdine University and his BA in Communications Studies from University of California – San Diego.

Faranak Atrzadeh

Senior VP Scientific Affairs & Marketing, Curetis USA

Faranak Atrzadeh joined Curetis USA Inc. in 2016 and serves as Senior Vice President of Scientific Affairs and Marketing. Prior to Curetis, Ms. Atrzadeh served as Senior Director of Strategic Marketing and Scientific Affairs for GenMark Diagnostics.

Ms. Atrzadeh has over 20 years of diagnostics experience and has served in various leadership positions across marketing, business development, scientific affairs, and R&D with GenMark Diagnostics, The Binding Site, Alere, Ventana Medical Systems, and DAKO Corporation.

Ms. Atrzadeh holds a B.A. in Biochemistry and Molecular Biology and an M.A. in Physiology and Cell Biology from University of California, Santa Barbara.

Dr. Andreas Posch

Managing Director Ares Genetics

Andreas Posch has joined Curetis as Director GEAR & BioIT in 2017. He joined from Siemens, where he was responsible for BioIT R&D at Siemens Healthcare as well as Software Sensors & Analytics with Siemens Corporate Technology.

As designated Principal Key Expert for Bioinformatics & Systems Medicine at Siemens Healthcare, he developed, executed and directed global innovation and R&D projects focusing on next-generation sequencing for diagnostic purposes, biomarker discovery, multi-scale disease modeling, advanced clinical decision support as well as genetic antibiotic resistance testing (GEAR).

He has an academic background in bioinformatics and biotechnology and his dissertation within the “Applied Bioscience Technology” program at the Vienna University of Technology was recognized by international awards while the industrial relevance of his thesis resulted in several million Euro funding from industry and competitive research grants.

Bernd Bleile, ass.iur.

General Counsel

Bernd Bleile has joined Curetis as General Counsel in February 2016. He is responsible for all legal affairs within Curetis, including general legal advice, workshops and trainings on legal topics, contract preparation and review, foundation and legal support of subsidiaries, contact for external lawyers, to appear in court etc.

Prior to Curetis, he worked in the area of law at “SMARTRAC”, a leading RFID product developing and manufacturing company, and at a former subsidiary of Daimler “MercedesBenz Technologies” in Sindelfingen. He qualified as a lawyer at the University of Tübingen and Higher Regional Court Stuttgart, and graduated as Master of Public Management (Dipl. Verwaltungswirt/FHöV – Rentenversicherung) at the University of Applied Sciences Ludwigsburg and German Federal Pension Fund Baden-Württemberg. In addition, he qualified as in-house data protection officer at TÜV-Süd.

Experienced and Diverse Supervisory Board

William Rhodes III

Chairman of the Supervisory Board

William E. Rhodes, III, has served as the chairman of the Supervisory Board since the IPO in 2015. Mr. Rhodes is a healthcare executive with more than 30 years of experience in the healthcare industry. During his 14-year career at Becton, Dickinson and Company (BD, 1998-2012), Mr. Rhodes held several senior leadership positions, including such roles as Worldwide President of BD Biosciences (2009-2011), a greater than US$ 1 billion revenue segment of BD. He was also an Executive Officer of BD, and was responsible for corporate strategy and merger and acquisition functions for all of BD’s businesses. Furthermore, he founded BD Ventures, the venture capital arm of Becton, Dickinson and Co. Prior to Becton Dickinson, he served in senior business development positions at Johnson & Johnson and Pfizer Inc. Mr. Rhodes also served as president at The William-James Co. and has a track record of over 20 successful acquisitions and divestitures. He was director of Andor Technologies plc (2013-2014), and has served on the boards of Novocell Inc., Conticare Medical, Vitagen Inc., the California Healthcare Institute, BIO, San Jose State University Research Foundation and Silicon Valley Leadership Group. He currently serves as director of Third Day Advisors LLC (since 2013), as director of Omega Group plc (since 2013), Paramit Corporation LLC (since 2014) and Cellector Corporation (since 2015), and as a member of the Advisory Board of Cayuga Venture Fund (since 2013). Mr. Rhodes has a number of advisory roles with Cornell University, including serving on the Advisory Councils of Mc Govern Family Center of Life Sciences (since 2013) and Entrepreneurship at Cornell (since 2015). He also was appointed to the Cornell College of Agriculture and Life Sciences Dean’s Council (2016) and serves as a Venture Consultant for Cornell’s Blackstone Launchpad (2016). Moreover, he is on the Editorial Board of the journal Clinical and Translational Medicine. Mr. Rhodes holds a Masters degree in International Business from Seton Hall University and a BSc degree from Cornell University. He originated eleven US patents for novel topical drugs and has been a lecturer on entrepreneurship in life sciences, innovation technology and M&A at Cornell University, Seton Hall University and San Jose State University.

Mario Crovetto

Chairman of the Audit Committee

Mario Crovetto has been appointed as the chairman of the Audit Committee upon the IPO. Mr. Crovetto has been working as an independent advisor on M&A and corporate projects, notably integrations, divestments and financing since 2011. From 1999 to 2011, he was the CFO of Eurand NV (Specialty Pharmaceuticals), which he took public to NASDAQ in 2007. In the 1990 to 1999 period he held various senior business positions at Recordati (Pharmaceuticals) including VP of Corporate Development, Division Manager of Diagnostics and CFO. Prior to that he held various positions at Montedison (Speciality Chemicals), Digital Equipment Corporation, Mobil and SIAR (Management Consulting). Mr. Crovetto holds a BSc in Economics from the Università Cattolica del Sacro Cuore, Milan and a master’s degree in Business Economics of Harvard University, Cambridge, MA.

Dr. Werner Schäfer

Vice Chairman

Dr. Werner Schäfer has been elected Vice Chairman of the Supervisory Board upon the IPO. He is a specialist in the in-vitro diagnostics industry and has nearly 30 years of management experience in this area, having held various international management positions throughout his career – including general management, marketing and R&D at major companies such as Behringwerke/Hoechst, Abbott, Boehringer Mannheim and Roche, for example. At Boehringer and Roche, he led the laboratory systems business unit and he served as a member of the executive board at Roche Diagnostics GmbH until 2001. Since then, he has worked as a consultant and serves on various executive boards and supervisory boards in highly specialized diagnostics and medical technology companies. He was a member of the supervisory boardof BRAHMS AG (2002 to 2009, sold to Thermo Fischer), mtm laboratories AG (2003 to 2011, sold to Roche) and Vivacta Limited (2006 to 2012, sold to Novartis), Signature AG (2012 to 2013), Genomatix Software GmbH (2011 to 2013) and Cognoptix Inc. (2009 to 2014). He currently serves as a member of the advisory board of Human GmbH (since 2005), as the Chairman of the Board of Directors at ProteoMediX AG (since 2012) and as Vice-Chairman of Curetis (previously Curetis AG – since 2014). Dr. Schaefer holds a Ph.D. in Chemistry from Philipps University Marburg.

Prabhavathi Fernandes, Ph.D.

Member of the Board

Dr. Prabhavathi Fernandes has been appointed member of the Supervisory Board. Until her retirement in December 2016, she was President and Chief Executive Officer and a Member of the Board of Directors of Cempra Pharmaceuticals, a company she has founded. In 2012, she led the initial public offering and listing on Nasdaq for Cempra, and has successfully raised over half a billion dollars to date for the company. Her career of more than four decades has focused on anti-infectives, first in clinical microbiology and infectious diseases and then in pharmaceutical discovery and development. Prior to Cempra, Dr. Fernandes held executive leadership positions at pharmaceutical corporations including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. She founded and led three biotechnology and CRO companies. She serves on the editorial board of several journals and she has authored over 250 publications and numerous reviews and book chapters.

Dr. Rudy Dekeyser

Member of the Board

Rudy Dekeyser, PhD, joined LSP in 2012. He became a Partner of the firm in that same year. Rudy’s prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Rudy was Managing Director of VIB, the Flanders Institute for Biotechnology, which he helped establish in 1995. Under his leadership, the Institute has grown to become one of Europe’s most successful incubators in the area of life sciences. From within the Institute, several top quality companies were established and numerous business development deals were struck with large industry players. Rudy brings company building skills to the LSP team. Over the years, Rudy has been appointed a Director of many companies and has been a senior Advisor to a number of investment firms. In addition, he currently chairs the Technology Transfer Board of the prestigious European molecular biology research institute EMBL in Heidelberg, Germany. Rudy also chairs the Valorisation Board of the Dutch Genomics Initiative (NGI), assembling top researchers from sixteen research centres in The Netherlands responsible for breakthroughs in the fields of health, agriculture and food. Rudy has a Master’s degree in zoology and a PhD in molecular biology from the University of Gent.

Dr. Nils Clausnitzer

Member of the Board

Dr. Nils Clausnitzer (Senior Vice President and President EMEA-APAC Lab and Distribution Services of VWR International llc./ VWR GmbH, Germany) has been elected into the Curetis Supervisory Board in June 2017. Dr. Clausnitzer has profound knowledge in sales and marketing of diagnostics and medical products. Prior to VWR International, he was President and Head of Commercial Operations, EMEA at Qiagen N.V. and General Manager for Olympus Germany. He also worked as Managing Director for Abbott Diagnostics Germany.

Scientific Advisory Board in Europe

Reno Frei, M.D.

Head of Clinical Microbiology

Reno Frei, MD, was Head of the Division of Clinical Microbiology, University Hospital Basel, Switzerland,  for  more  than  25  years.  His  research  focuses  on  antibiotic  resistance, microbiological diagnostics, and healthcare-associated infections including prosthetic device infections and sepsis. He has published 250 peer-reviewed articles and book chapters. Dr. Frei received his medical degree from the University of Basel Faculty of Medicine in 1980. He completed his training in infectious diseases and laboratory medicine with a research fellowship at the University of Iowa College of Medicine, Iowa City, USA.

Dr. Laurent Poirel

Associate Professor of Microbiology

Dr. Laurent Poirel works as Associate Professor in the Microbiology Unit, Department of Medicine of the Faculty of Science at the University of Fribourg, Switzerland (director: Prof. Patrice Nordmann). He has a long-standing scientific career at the French National Institute of Health and Medical Research (INSERM) in Paris / France. His research area is genetics, biochemistry and epidemiology of antibiotic resistance determinants with focus on ß-lactam, aminoglycoside, carbapenem and quinolone resistances. In addition, he and his team have jointly developed a variety of rapid diagnostic tests for detection of extended-spectrum ß-lactamases and carbapenemases. Dr. Poirel has co-authored more than 430 publications in peer-reviewed journals and is frequently invited speaker at international science and industry conferences including among others the International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the European Congress for Clinical Microbiology and Infectious Diseases (ECCMID). In addition, he is a member of both, the ICAAC Program Committee and the ESCMID Executive Subcommittee and serves as editor or member on editorial board of various international journals.

Jean-Louis Vincent, MD, PhD

Professor of Intensive Care

Jean-Louis Vincent, MD, PhD, is Professor of Intensive Care at the University of Brussels and Intensivist in the Department of Intensive Care at the Erasme University Hospital in Brussels, Belgium. He has published more than 900 peer-reviewed articles, some 400 book chapters and review articles, 950 original abstracts, and has edited 101 books. Among others, he is the Editor-In-Chief of Critical Care, Current Opinion in Critical Care and ICU Management and a member of the editorial boards of about 30 other journals. Jean-Louis Vincent received numerous awards, including the prestigious Prix Scientifique Joseph Maisin-Sciences biomédicales cliniques.Prof. Vincent is a Past-President of the European Society of Intensive Care Medicine and presently President of the World Federation of Societies of Intensive and Critical Care Medicine.